Catecholamine-Induced Cardiomyopathy in Pheochromocytoma: How to Manage a Rare Complication in a Rare Disease?

Abstract

Pheochromocytomas and paragangliomas (PHEOs) are rare neuroendocrine tumors. Clinical manifestations include different cardiovascular signs and symptoms, which are related to excessive secretion of catecholamines. Catecholamine-induced cardiomyopathy in PHEO (CICMPP) is a rare but dreaded complication of PHEO. Once patient is diagnosed with this condition, the prognosis is worse and a surgical risk is much higher than expected. This article focuses on how catecholamines affect the heart and the pathophysiologic mechanism of CICMPP. The cardiovascular responses to catecholamine depend mostly on which catecholamine is released as well as the amount of catecholamine that is released. The acute release of norepinephrine and epinephrine from PHEO increases heart rate, systemic vascular resistance, myocardial contractility, and reduces venous compliance. The excessive adrenergic stimulation by catecholamine results in severe vasoconstriction and coronary vasospasm, myocardial ischemia, and subsequently damage, and necrosis. Chronically elevated catecholamine levels lead to significant desensitization of cardiac β-adrenoceptors. The increased levels of the enzyme β-adrenoceptors kinase (βARK) in the heart seems to mediate these biochemical and physiological changes that are consistently correlated with attenuated responsiveness to catecholamine stimulation. Through these mechanisms different types of cardiomyopathy (CMP) can be formed. This review discusses extensively the 3 types of cardiomyopathies that can be present in a PHEO patient. It also provides the clinical presentation and diagnostic and therapeutic algorithm in managing patients with CICMPP.

Key words

cardiomyopathy - pheochromocytoma - paraganglioma - catecholamine

Publikationsverlauf

Eingereicht: 26. Juli 2017

Angenommen: 31. Juli 2018

Artikel online veröffentlicht:
18. September 2018

• References

• 1 Klein I. Endocrine Disorders and Cardiovascular Disease. Braunwald’s Heart Disease a Textbook of Cardiovascular Medicine. 10th edition Mann DL, Zipes DP, Libby P, Bonow RO, Braunwald E. (eds) Philadelphia: Elsevier Saunders; 2015: 1793–1808
• 2 Pacak K, Chrousos GP, Koch CA, Lenders JW, Eisenhofer G. Pheochromocytoma: Progress in diagnosis, therapy, and genetics. In: Margioris A, Chrousos GP. (eds) Adrenal Disorders. 1 ed. Vol 1:Totowa: Humana Press; 2001: 479–523
• 3 Bajwa SS, Bajwa SK. Implications and considerations during pheochromocytoma resection: A challenge to the anesthesiologist. Indian J Endocrinol Metab 2011; 5 (Suppl. 04) S337-S344
• 4 Kantorovich V, Pacak K. Pheochromocytoma and paraganglioma. Prog Brain Res 2010; 182: 343-373
• 5 Bravo EL. Evolving Concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. Endocr Rev 1994; 15: 356-368
• 6 Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant Hypertension: Diagnosis, evaluation, and treatment: A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51: 1403-1419
• 7 Zuber SM, Kantorovich V, Pacak K. Hypertension in pheochromocytoma: Characteristics and treatment. Endocrinol Metab Clin North Am 2011; 40: 295-311
• 8 Kalra Y, Agarwal H, Smith A. Perioperative management of pheochromocytoma and catecholamine-induced dilated cardiomyopathy in a pediatric patient. Pediatr Cardiol 2013; 34: 2013-3016
• 9 Kobayashi Y, Kobayashi Y. Pheochromocytoma Found in Takotsubo Cardiomyopathy Patients. J Invasive Cardiol 2014; 26: E76-E77
• 10 Yang YN, Chuang YC, Yin WH, Young MS. Catecholamine-Induced Cardiomyopathy Secondary to Pheochromocytoma Mimicking Fulminant Acute Myocarditis. Acta Cardiol Sin 2007; 23: 125-130
• 11 Huddle KR, Kalliatakis B, Skoularigis J. Pheochromocytoma associated with clinical and echocardiographic features simulating hypertrophic obstructive cardiomyopathy. Chest 1996; 109: 1394-1397
• 12 Park JH, Kim KS, Sul JY, Shin SK, Kim JH, Lee JH, Choi SW, Jeong J, Seong I. Prevalence and patterns of left ventricular dysfunction in patients with pheochromocytoma. J Cardiovasc Ultrasound 2011; 19: 76-82
• 13 Giavarini A, Chedid A, Bobrie G, Plouin P, Hagege A, Amar L. Acute catecholamine cardiomyopathy in patients with phaeochromocytoma or functional paraganglioma. Heart 2013; 99: 1438-1444
• 14 Kassim TA, Clarke DD, Mai VQ, Clyde PW, Mohamed SA, Shakir KM. Catecholamine-induced cardiomyopathy. Endocr Pract 2008; 14: 1137-1149
• 15 Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: A contemporary view with implications for physiology and medicine. Pharmacol Rev 2004; 56: 331-349
• 16 Schulz C, Eisenhofer G, Lehnert H. Principles of catecholamine biosynthesis, metabolism, and release. Front Horm Res 2004; 31: 1-25
• 17 Gordan R, Gwathmey JK, Xie LH. Autonomic and endocrine control of cardiovascular function. World J Cardiol 2015; 7: 204-214
• 18 Brodde OE, Michel MC. Adrenergic and Muscarinic Receptors in the Human Heart. Pharmacol Rev 1999; 51: 651-689
• 19 Adameova A, Abdellatif Y, Dhalla NS. Role of the excessive amounts of circulating catecholamines and glucocorticoids in stress-induced heart disease. Can J Physiol Pharmacol 2009; 87: 493-514
• 20 Klabunde RE. Neurohumoral Control of the Heart and Circulation. Cardiovascular Physiology Concepts. 2nd edition Lippincott Williams and Wilkins; 2012: 117-139
• 21 Rona G. Catecholamine Cardiotoxicity. J Mol Cell Cardiol 1985; 17: 291-306
• 22 Fleckenstein A, Janke J, Doring HJ, Pachinger O. Ca overload as determinant factor in the production of catecholamine induced myocardial lesion. In: Bajusz E, Rona G, Brink AJ, Lochner A. (ed) Recent Advances in Studies on Cardiac Structure and Metabolism. Vol 2: Baltimore, MD: University Park Press; 1973: 455–466
• 23 Bloom S, Davis DL. Calcium as mediator of isoproterenol-induced myocardial necrosis. AM J Pathol 1972; 69: 459-470
• 24 Fowler MB, Laser JA, Hopkins GL, Minobe WB, Bristow MR. Assessment of the β-adrenergic receptor pathway in the intact failing human heart: Progressive receptor down-regulation and subsensitivity to agonist response. Circulation 1986; 74: 1291-1301
• 25 Koch WJ, Milano CA, Lefkowitz RJ. Transgenic manipulation of myocardial G protein-coupled receptors and receptor Kinases. Circ Res 1986; 74: 1291-1301
• 26 Pitcher JA, Freedman NJ, Lefkowitz RJ. G protein-coupled receptor kinases. Annu Rev Biochem 1998; 67: 653-692
• 27 Chen Y, Best JA, Nagamoto K, Tan AW. Regulation of tyrosine hydroxylase gene expression by the m1 muscarinic acetycholine receptor in rat pheochromocytoma cells. Brain Res Mol Brain Res 1996; 40: 42-54
• 28 Attar MN, Moulik PK, Salem GD, Rose EL, Khaleeli AA. Phaeochromocytoma presenting as dilated cardiomyopathy. Int J Clin Pract 2003; 57: 547-548
• 29 Radtke WE, Kazmier FJ, Rutherford BD, Sheps SG. Cardiovascular complications of pheochromocytoma crisis. Am J Cardiol 1975; 35: 701-705
• 30 Costa VM, Carvalho F, Bastos ML, Carvalho RA, Carvalho M, Remiao F. Contribution of catecholamine reactive intermediates and oxidative stress to the pathologic features of heart diseases. Curr Med Chem 2011; 18: 2272-2314
• 31 Khan MU, Cheema Y, Shahbaz AU, Ahokas RA, Sun Y, Gerling IC, Bhattacharya SK, Weber KT. Mitochondria play a central role in nonischemic cardiomyocyte necrosis: Common to acute and chronic stressor states. Pflugers Arch 2012; 464: 123-131
• 32 Amin JK, Xiao L, Pimental DR, Pagano PJ, Singh K, Sawyer DB, Colucci WS. Reactive oxygen species mediate α-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes. J Mol Cell Cardiol 2001; 33: 131-139
• 33 Behonick GS, Novak MJ, Nealley EW, Baskin SI. Toxicology update: the cardiotoxicity of the oxidative stress metabolites of catecholamines (aminochromes). J Appl Toxicol 2001; 21 (Suppl. 01) S15-S22
• 34 Bindoli A, Rigobello MP, Galzigna L. Toxicity of aminochromes. Toxicol Lett 1989; 48: 3-20
• 35 Bindoli A, Deeble DJ, Rigobello MP, Galzigna L. Direct and respiratory chain-mediated redox cycling of adrenochrome. Biochim Biophys Acta 1990; 1016: 349-356
• 36 Green DE, Richter D. Adrenaline and adrenochrome. Biochem J 1937; 31: 596-616
• 37 Beamish RE, Dhillon KS, Singal PK, Dhalla NS. Protective effect of sulfinpyrazone against catecholamine metabolite adrenochrome-induced arrhythmias. Am Heart J 1981; 102: 149-152
• 38 Yates JC, Beamish RE, Dhalla NS. Ventricular dysfunction and necrosis produced by adrenochrome metabolite of epinephrine: Relation to pathogenesis of catecholamine cardiomyopathy. Am Heart J 1981; 102: 210-221
• 39 Taam GM, Takeo S, Ziegelhoffer A, Singal PK, Beamish RE, Dhalla NS. Effect of adrenochrome on adenine nucleotides and mitochondrial oxidative phosphorylation in rat heart. Can J Cardiol 1986; 2: 88-93
• 40 Zhang R, Gupta D, Albert SG. Pheochromocytoma as a reversible cause of Cardiomyopathy: Analysis and review of the literature. Int J Cardiol 2017; 249: 319-323
• 41 Sanchez MA, Esteban MR, Pineda SO, Ortiz MR, Peña ER, Rubio DM, Belsue FV. Clinical outcome and reversibility of systolic dysfunction in patients with dilated cardiomyopathy due to hypertension and chronic heart failure. Rev Esp Cardiol 2004; 57: 834-841
• 42 Ferreira VM, Marcelino M, Piechnik SK, Marini C, Karamitsos TD, Ntusi NAB, Francis JM, Robson MD, Arnold JR, Thomas JDJ, Herincs M, Hassan-Smith ZK, Greiser A, Wiebke A, Korbonits M, Karavitaki N, Grossman AB, Wass JAH, Neubauer S. Pheochromocytoma Is Characterized by Catecholamine-Mediated Myocarditis, Focal and Diffuse Myocardial Fibrosis, and Myocardial Dysfunction. JACC 2016; 67: 2364-2374
• 43 Lyon AR, Rees PS, Prasad S, Poole-Wilson PA, Harding SE. Stress (Takotsubo) cardiomyopathy – a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. Nat Clin Pract Cardiovasc Med 2008; 5: 22-29
• 44 Batisse-Lignier M, Pereira B, Motreff P, Pierrard R, Burnot C, Magdasy S, Roche B, Desbiez F, Clerfond G, Citron B, Lusson JR, Tauveron I, Eschaller R. Acute and Chronic Pheochromocytoma-Induced Cardiomyopathies: Different Prognoses? : A Systematic Analytic Review. Medicine (Baltimore) 2015; 94: e298
• 45 Schurmeyer TH, Engeroff B, Dralle H, Muhlen VZ. Cardiological Effect of Catecholamine–Secreting Tumours. Eur J Clin Invest 1997; 27: 189-195
• 46 Sadowski D, Cujec B, McMeekin JD, Wilson TW. Reversibility of catecholamine-induced cardiomyopathy in a woman with pheochromocytoma. CMAJ 1989; 141: 923-924
• 47 de Miguel V, Arias A, Paissan A, de Arenaza DP, Pietrani M, Jurado A, Jaen A, Fainstein Day P. Catecholamine-induced myocarditis in pheochromocytoma. Circulation 2014; 129: 1348-1349
• 48 Matias-Guiu JA, Ramos-Levi A, Sanabria-Perez C. Catecholamine-induced cardiomyopathy triggered by pheochromocytoma. Endocrinol Nutr 2011; 58: 204-206
• 49 Brilakis ES, Young Jr WF, Wilson JW, Thompson GB, Munger TM. Reversible catecholamine-induced cardiomyopathy in a heart transplant candidate without persistent or paroxysmal hypertension. J Heart Lung Transplant 1999; 18: 376-380
• 50 Riester A, Weismann D, Quinkler M, Lichtenauer UD, Sommerrey S, Halbritter R, Penning R, Spitzweg C, Schopohl J, Beuschlein F, Reincke M. Life-threatening events in patients with pheochromocytoma. Eur J Endocrinol 2015; 173: 757-764
• 51 Hekimian G, Kharcha F, Brechot N, Schmidt M, Ghander C, Lebreton G, Girerd X, Tresallet C, Trouillet JL, Leprinc P, Chastre J, Combes A, Luyt CE. Extracorporeal membrane oxygenation for pheochromocytoma-induced cardiogenic shock. Ann Intens Care 2016; 6: 117
• 52 Tagawa M, Nanba H, Suzuki H, Nakamura Y, Uchiyama H, Ochiai S, Terunuma M, Yahata K, Minamino T. Ventricular Rhythm and Hypotension in a Patient with Pheochromocytoma-induced Myocardial Damage and Reverse Takotsubo Cardiomyopathy. Intern Med 2015; 54: 2343-2349
• 53 Naderi N, Amin A, Setayesh A, Pouraliakbar H, Mozaffari K, Maleki M. Pheochromocytoma-induced reverse tako-tsubo with rapid recovery of left ventricular function. Cardiol J 2012; 19: 527-531
• 54 Long SL, Whitlock RP, Schwalm JDR. Pheochromocytoma-induced reverse Takotsubo cardiomyopathy leading to fulminant pulmonary edema: Successful intervention with an impella CP® percutaneous ventricular assist device. J Cardiol Clin Res 2016; 4: 1068
• 55 Kim TS, Chu EH, Kang HH, Chun SW, Cho EJ, Kim JH. A case of reversal of Takotsubo cardiomyopathy in patient with pheochromocytoma. J Cardiovasc Ultrasound 2007; 15: 50-54
• 56 Falk RH, Hershberger RE. The Dilated, Restrictive, and Infiltrative Cardiomyopathies. Braunwald’s Heart Disease a Textbook of Cardiovascular Medicine. 10th edition Mann DL, Zipes DP, Libby P, Bonow RO, Braunwald E. (eds)Philadelphia: Elsevier Saunders; 2015: 1551–1573
• 57 Wittstein IS, Thiemann DR, Iiama JA, Baughman KL, Schulman SP, Gerstenblith G, Wu KC, Rade JJ, Bivalacqua TJ, Hunter CC. Neurohumural features of myocardial stunning due to sudden emotional stress. N Engl J Med 2005; 352: 539-548
• 58 Agarwal V, Kant G, Hans N, Messerl FH. Takotsubo-like cardiomyopathy in pheochromocytoma. Int J Cardiol 2001; 153: 241-248
• 59 Di Valentino M, Balestra GM, Christ M, Raineri I, Oertli D, Zellweger MJ. Inverted Takotsubo cardiomyopathy due to pheochromocytoma. Eur Heart J 2008; 29: 830
• 60 Sanchez-Recalde A, Costero O, Oliver JM, Iborra C, Ruiz E, Sobrino JA. Images in cardiovascular medicine. Pheochromocytoma-related cardiomyopathy: Inverted Takotsubo contractile pattern. Circulation 2006; 113: e738-e739
• 61 Maron BJ, Olivotto I. Hypertrophic cardiomyopathy. Braunwald’s Heart Disease a Textbook of Cardiovascular Medicine 10th edition. Mann DL, Zipes DP, Libby P, Bonow RO, Braunwald E. (eds) Philadelphia: Elsevier Saunders; 2015: 1574-1588
• 62 Jacob JL, da Silveira LC, de Freitas CG, Centola CA, Nicolau JC, Lorga AM. Pheochromocytoma with echocardiographic features of obstructive hypertrophic Cardiomyopathy. A case report. Angiology 1994; 45: 958-959
• 63 Golbasi Z, Sakalli M, Cicek D, Aydogdu S. Dynamic left ventricular outflow tract obstruction in a patient with pheochromocytoma. Jpn Heart J 1999; 40: 831-835
• 64 Jozwik-Plebanek K, Klisiewicz A, Januszewicz A, Prejbisz A. Transient dynamic left ventricular outflow tract obstruction in a Patient with pheochromocytoma. Kardiol Pol 2014; 72: 472
• 65 Jayaprasad N, Madhavan S. Pheochromocytoma presenting as acute myocardial infarction. Nepal Heart J 2015; 12: 89-92
• 66 Jang SY, Yang DH, Lee SH, Kim JH, Park SH, Park HS, Cho Y, Chae S, Jun JE, Park WH. Recurrent catecholamine-induced cardiomyopathy in a patient with a pheochromocytoma. Korean Circ J 2009; 39: 254-257
• 67 Suh IW, Lee CW, Kim YH, Hong MK, Lee JW, Kim JJ, Park SW, Park SJ. Catastrophic catecholamine-induced cardiomyopathy mimicking acute myocardial infarction, rescued by extracorporeal mebrane oxygenation (ECMO) in pheochromocytoma. J Korean Med Sci 2008; 23: 350-354
• 68 De Backer TL, De Buyzere ML, Taeymans Y, Kunnen P, Rubens R, Clement DL. Cardiac involvement in pheochromocytoma. J Hum Hypertens 2000; 14: 469-471
• 69 Sanna GD, Talanas G, Fiore G, Canu A, Terrosu P. Pheochromocytoma presenting as an acute coronary syndrome complicated by acute heart failure: The challenge of great mimic. J Saudi Heart Assoc 2016; 28: 278-282
• 70 Scanlon PJ, Faxon DP, Audet AM, Carabello B, Dehmer GJ, Eagle KA, Legako RD, Leon DF, Murray JA, Nisse SE, Pepine CJ, Watson RM, Ritche JL, Gibbons RJ, Cheitlin MD, Garson Jr. A, Russell Jr. RO, Ryan TJ, Smith Jr. SC. ACC/AHA guidelines for coronary angiography. J Am Coll Cardiol 1999; 33: 1756-1824
• 71 Prejbisz A, Lenders JW, Eisenhofer G, Januszewicz A. Cardiovascular manifestations of phaeochromocytoma. J Hypertens 2011; 29: 2049-2060
• 72 van Iperen CE, Giezen J, Kramer WL, Lips CJ, Bartelink AK. Acute dyspnea resulting from pulmonary oedema as the first sign of a phaeochromocytoma. Respiration 2001; 68: 323-326
• 73 Nepal S, Giri S, Bhusal M, Siwakoti K, Pathak R. An uncommon cause of acute pulmonary edema. JAAPA 2016; 29: 1-4
• 74 Takeshita T, Shima H, Oishi S, Machida N, Uchiyama K. Noncardiogenic pulmonary edema as the first manifestation of pheochromocytoma: case report. Radiat Med 2005; 23: 133-138
• 75 Malek LA, Werys K, Klopotowski M, Spiewak M, Milosz-Wleczorek B, Mazurkiewicz L, Petryka-Mazurkiewicz J, Marczak M, Witkowski A. Native T1-mapping for non-contrast assessment of myocardial fibrosis in patients with hypertrophic cardiomyopathy—comparison with late enhancement quantification. Magn Reson Imaging 2015; 33: 718-724
• 76 Puntmann VO, Voigt T, Chen Z, Mayr M, Karim R, Rhode K, Pastor A, Carr-White G, Razavi R, Schaeffter T, Nagel E. Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. JACC Cardiovasc Imaging 2013; 6: 475-484
• 77 Lenders JW, Eisenhofer G, Manneli M, Pacak K. Pheochromocytoma. Lancet 2005; 366: 665-675
• 78 Li SJ, Wang T, Wang L, Pang ZQ, Ma B, Li YW, Yang J, Dong H. Ventricular Tachycardia and Resembling Acute Coronary Syndrome During Pheochromocytoma Crisis. A case Report. Medicine (Baltimore) 2016; 95: e3297
• 79 Kokkonen JO, Lammintausta O, Luomanmaki K. Acute heart failure and transient low voltage in electrocardiogram after massive catecholamine release from a phaeochromocytoma. Eur Heart J 1997; 18: 1357
• 80 Choi SY, Cho KI, Han YJ, You GI, Kim JH, Heo JH, Kim HS, Cha TJ, Lee JW. Impact of Pheochromocytoma on Left Ventricular Hypertrophy and QTc Prolongation: Comparison with Takotsubo Cardiomyopathy. Koren Circ J 2014; 44: 89-96
• 81 Cheng TO, Bashour TT. Striking electrocardiographic changes associated with pheochromocytoma. Masquerading as ischemic heart disease. Chest 1976; 70: 397-399
• 82 Zweiker R, Tiemann M, Eber B, Schumacher M, Fruhwald FM, Lipp R, Lax S, Pristautz H, Klein W. Bradydysrhythmia-related presyncope secondary to pheochromocytoma. J Intern Med 1997; 242: 249-253
• 83 Shimizu K, Miura Y, Meguro Y, Noshiro T, Ohzeki T, Kusakari T, Akama H, Watanabe T, Honma H, Imai Y, Yoshinaga K, Totsuka H. QT prolongation with torsades de pointes in pheochromocytoma. Am Heart J 1992; 124: 235-239
• 84 Hajdusek P, Pazdernik M, Kettner J, Kautzner J. Pheochromocytoma as a rare cause of ventricular fibrillation. Interv Akut Kardiol 2016; 15: 187-190
• 85 Delekta J, Riahi S, Eschen O. Rare cause of ventricular tachycardia: Pheochromocytoma. J Cardiol Cases 2015; 11: 62-65
• 86 Methe H, Hinterseer M, Wilbert-Lampen U, Beckmann BM, Steinbeck G, Kaab S. Torsades de Pointes: A rare complication of an extra-adrenal pheochromocytoma. Hyperten Res 2007; 30: 1263-1266
• 87 Shaw TR, Rafferty P, Tait GW. Transient Shock and myocardial impairment caused by phaeochromocytoma crisis. Br Heart J 1987; 57: 194-198
• 88 Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young Jr WF. Endocrine Society. Pheochromocytoma and paraganglioma: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99: 1915-1942
• 89 Olson SW, Deal LE, Piesman M. Epinephrine-secreting pheochromocytoma presenting with cardiogenic shock and profound hypocalcemia. An Intern Med 2004; 140: 849-851
• 90 Brukamp K, Goral S, Townsend RR, Silvestry FE, Torigian DA. Rapidly reversible cardiogenic shock as a pheochromocytoma presentation. Am J Med 2007; 120: e1-e2
• 91 Grasselli G, Foti G, Patroniti N, Rona R, Perlangeli MV, Pesenti A. Extracorporeal cardiopulmonary support for cardiogenic shock caused by pheochromocytoma: A case report and literature review. Anesthesiology 2008; 108: 959-962
• 92 Kizer JR, Koniaris LS, Edelman JD, St John Suton MG. Pheochromocytoma crisis, cardiomyopathy, and hemodynamic collapse. Chest 2000; 118: 1221-1223
• 93 Bergland BE. Pheochromocytoma presenting as shock. Am J Emerg Med 1989; 7: 44-48
• 94 Chatzizisis YS, Ziakas A, Feloukidis C, Paramythiotis D, Hadjimiltiades S, Iliadis A, Basdanis G, Styliadis I. Pheochromocytoma crisis presenting with cardiogenic shock. Herz 2014; 39: 156-160
• 95 Benowitz NL. Pheochromocytoma-recent advances in diagnosis and treatment. West J Med 1988; 148: 561-567
• 96 Satendra M, de Jesus C, Bordalo e Sa AL, Rosario L, Rocha J, Bicha Castelo H, Correia MJ, Nunes Diogo A. Reversible catecholamine-induced cardiomyopathy due to pheochromocytoma. Rev Port Cardiol 2014; 33: 177.e1-177.e6
• 97 Casey RT, Challis BG, Pitfield D, Mahroof RM, Jamieson N, Bhagra CJ, Vulysteke A, Pettit SJ, Chatterjee KC. Management of an acute catecholamine-induced cardiomyopathy and circulatory collapse: A multidisciplinary approach. Endocrinol Diabtes Metab Case Rep 2017; pii: 17-0122
• 98 Steppan J, Shields J, Lebron R. Pheochromocytoma presenting as acute heart failure leading to cardiogenic shock and multiorgan failure. Case Rep Med 2011; 2011: 596354
• 99 Mavrogeni S, Markousis-Mavrogenis G, Markussis V, Kolovou G. The Emerging Role of Cardiovascular Magnetic Resonance Imaging in the Evaluation of Metabolic Cardiomyopathies. Horm Metab Res 2015; 47: 623-632
• 100 Jessurun CR, Adam K, Moise Jr. KJ, Wilansky S. Pheochromocytoma-induced myocardial infarction in pregnancy. A case report and literature review. Tex Heart Inst J 1993; 20: 120-122
• 101 Scholten A, Cisco RM, Vriens MR, Cohen JK, Mitmaker EJ, Liu C, Tyrrell JB, Shen WT, Duh QY. Pheochromocytoma Crisis is not a Surgical Emergency. J Clin Endocrinol Metab 2013; 98: 581-591
• 102 Pacak K. Preoperative management of the pheochromocytoma patient. J of Clin Endocrinol Metab 2007; 92: 4069-4079
• 103 McMillian WD, Trombley BJ, Charash WE, Christian RC. Phentolamine continuous infusion in a patient with pheochromocytoma. Am J Health Syst Pharm 2011; 6: 130-134
• 104 Taliercio JJ, Bravo E. An unusual presentation of pheochromocytoma. NDT Plus 2011; 4: 331-334
• 105 Ritter S, Guertler T, Meier CA, Genoni M. Cardiogenic shock due to pheochromocytoma rescued by extracorporeal membrane oxygenation. Interact Cardiovasc Thorac Surg 2011; 13: 112-113
• 106 Whitelaw BC, Prague JK, Mustafa OG, Schulte KM, Hopkins PA, Gilbert JA, McGregor AM, Aylwin SJ. Phaeochromocytoma [corrected] crisis. Clin Endocrinol (Oxf) 2014; 80: 13-22
• 107 Salathe M, Weiss O, Ritz R. Rapid reversal of heart failure in a patient with phaeochromocytoma and catecholamine-induced cardiomyopathy who was treated with captopril. Br Heart J 1992; 68: 527-528
• 108 Dzau VJ. Cardiac Renin-Angiotensin System: Molecular and Functional Aspects. AM J Med 1988; 84: 22-27